The UK and US have hammered out a important trade agreement that will keep zero duties on British medicine shipments being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the public health system. This move ensures that duties on these key products will be held at zero for a period of 36 months.
This development follows earlier threats to dramatically increase duties on branded pharmaceutical products, with figures floated as high as 100%.
"This deal between the United Kingdom strengthens the international landscape for cutting-edge drugs and establishes much-needed fairness to American-British pharmaceutical trade," a release declared.
Trade Importance
Pharmaceuticals represent one of the Britain's most significant goods shipped to the US, which is clearly the biggest market for major UK drugmakers.
Trade data show that in the year prior to September, the UK exported drugs valued at £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that span.
"This guarantee safeguards employment, stimulates funding and paves the way for the UK to become a worldwide center for biotech and pharma," a minister remarked.
Key British Pledges
The deal entails several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to double overall NHS spending on drugs from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. In the past, rebates topped twenty percent.
Broader Context
The deal takes place against a ongoing tension between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
These tensions were heightened by arguments that American consumers were paying significantly more for the same drugs than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been paused or abandoned, while major investments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
